174 related articles for article (PubMed ID: 38141128)
21. [Third degree atrio-ventricular blockade during a myocarditis occurring under anti-PD1 : Case report and literature review].
Prevel R; Colin G; Calès V; Renault PA; Mazieres J
Rev Med Interne; 2020 Apr; 41(4):284-288. PubMed ID: 31983550
[TBL] [Abstract][Full Text] [Related]
22. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors.
Moreira A; Loquai C; Pföhler C; Kähler KC; Knauss S; Heppt MV; Gutzmer R; Dimitriou F; Meier F; Mitzel-Rink H; Schuler G; Terheyden P; Thoms KM; Türk M; Dummer R; Zimmer L; Schröder R; Heinzerling L
Eur J Cancer; 2019 Jan; 106():12-23. PubMed ID: 30453170
[TBL] [Abstract][Full Text] [Related]
23. Nivolumab-induced Myositis and Myocarditis with Positive Anti-titin Antibody and Anti-voltage-gated Potassium Channel Kv1.4 Antibody.
Ono R; Iwai Y; Yamazaki T; Takahashi H; Hori Y; Fukushima K; Saotome T
Intern Med; 2022 Oct; 61(19):2973-2979. PubMed ID: 35314545
[TBL] [Abstract][Full Text] [Related]
24. Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series.
Coustal C; Vanoverschelde J; Quantin X; Lesage C; Michot JM; Lappara A; Ederhy S; Assenat E; Faure M; Issa N; Lambotte O; Puyade M; Dereure O; Tosi D; Rullier P; Serre I; Larcher R; Klouche K; Chanques G; Vernhet-Kovacsik H; Faillie JL; Agullo A; Roubille F; Guilpain P; Maria ATJ
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37258037
[TBL] [Abstract][Full Text] [Related]
25. Myositis as a neuromuscular complication of immune checkpoint inhibitors.
Vermeulen L; Depuydt CE; Weckx P; Bechter O; Van Damme P; Thal DR; Claeys KG
Acta Neurol Belg; 2020 Apr; 120(2):355-364. PubMed ID: 31993961
[TBL] [Abstract][Full Text] [Related]
26. Consider Myocarditis When Patients Treated with Immune Checkpoint Inhibitors Present with Ocular Symptoms.
Rhee JY; Torun N; Neilan TG; Guidon AC
Oncologist; 2022 May; 27(5):e402-e405. PubMed ID: 35348772
[TBL] [Abstract][Full Text] [Related]
27. Case Report: Glucocorticoid Effect Observation in a Ureteral Urothelial Cancer Patient With ICI-Associated Myocarditis and Multiple Organ Injuries.
Hu X; Wei Y; Shuai X
Front Immunol; 2021; 12():799077. PubMed ID: 34975911
[TBL] [Abstract][Full Text] [Related]
28. Role of Biomarkers in the Management of Immune-Checkpoint Inhibitor-Related Myocarditis.
Vasbinder A; Ismail A; Salem JE; Hayek SS
Curr Cardiol Rep; 2023 Sep; 25(9):959-967. PubMed ID: 37436648
[TBL] [Abstract][Full Text] [Related]
29. Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians.
Raschi E; Rossi S; De Giglio A; Fusaroli M; Burgazzi F; Rinaldi R; Potena L
Drug Saf; 2023 Sep; 46(9):819-833. PubMed ID: 37341925
[TBL] [Abstract][Full Text] [Related]
30. Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study.
Xie X; Wang L; Li Y; Xu Y; Wu J; Lin X; Lin W; Mai Q; Chen Z; Zhang J; Xie Z; Qin Y; Liu M; Lu M; Luo B; Zhou C
Front Immunol; 2022; 13():879900. PubMed ID: 35924238
[TBL] [Abstract][Full Text] [Related]
31. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.
Mahmood SS; Fradley MG; Cohen JV; Nohria A; Reynolds KL; Heinzerling LM; Sullivan RJ; Damrongwatanasuk R; Chen CL; Gupta D; Kirchberger MC; Awadalla M; Hassan MZO; Moslehi JJ; Shah SP; Ganatra S; Thavendiranathan P; Lawrence DP; Groarke JD; Neilan TG
J Am Coll Cardiol; 2018 Apr; 71(16):1755-1764. PubMed ID: 29567210
[TBL] [Abstract][Full Text] [Related]
32. Immune checkpoint inhibitor-induced myocarditis, myositis, myasthenia gravis and transaminitis: a case series and review.
Wai Siu DH; O'Neill RS; Harris CA; Wang J; Ardolino L; Downton T; Tong M; Hong JH; Chin V; Clingan PR; Aghmesheh M; Soudy H
Immunotherapy; 2022 May; 14(7):511-520. PubMed ID: 35321560
[TBL] [Abstract][Full Text] [Related]
33. Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program.
Naqash AR; Moey MYY; Cherie Tan XW; Laharwal M; Hill V; Moka N; Finnigan S; Murray J; Johnson DB; Moslehi JJ; Sharon E
J Clin Oncol; 2022 Oct; 40(29):3439-3452. PubMed ID: 35658474
[TBL] [Abstract][Full Text] [Related]
34. Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis.
Cautela J; Zeriouh S; Gaubert M; Bonello L; Laine M; Peyrol M; Paganelli F; Lalevee N; Barlesi F; Thuny F
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33298621
[TBL] [Abstract][Full Text] [Related]
35. Value of troponin T versus I in the diagnosis of immune checkpoint inhibitor-related myocarditis and myositis: rechallenge?
Rossi VA; Gawinecka J; Dimitriou F; von Eckardstein A; Dummer R; Ruschitzka F; Matter CM
ESC Heart Fail; 2023 Aug; 10(4):2680-2685. PubMed ID: 37021424
[TBL] [Abstract][Full Text] [Related]
36. Pembrolizumab-induced myocarditis with complete atrioventricular block and concomitant myositis in a metastatic bladder cancer patient: a case report and review of the literature.
Saad R; Ghaddar A; Zeenny RM
J Med Case Rep; 2024 Feb; 18(1):107. PubMed ID: 38383436
[TBL] [Abstract][Full Text] [Related]
37. Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: Pathway toward precision-based therapy.
Balanescu DV; Donisan T; Palaskas N; Lopez-Mattei J; Kim PY; Buja LM; McNamara DM; Kobashigawa JA; Durand JB; Iliescu CA
Cardiovasc Pathol; 2020; 47():107211. PubMed ID: 32268262
[TBL] [Abstract][Full Text] [Related]
38. Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicity.
Wang Y; Ertl C; Schmitt C; Hammann L; Kramer R; Grabmaier U; Schöberl F; Anz D; Piseddu I; Pesch G; Vera J; Froehlich W; Weckbach L; Tomsitz D; Loquai C; Zimmer L; Mangana J; Dummer R; Gutzmer R; Klespe KC; Stege H; Meiss F; Thoms KM; Terheyden P; Bröckelmann PJ; Johnson DB; French LE; Heinzerling L
Front Cardiovasc Med; 2024; 11():1408586. PubMed ID: 38915743
[TBL] [Abstract][Full Text] [Related]
39. Fatal myositis and spontaneous haematoma induced by combined immune checkpoint inhibitor treatment in a patient with pancreatic adenocarcinoma.
Liu Y; Liu Z; Zeng X; Bai C; Chen L; Lin S; Tian X
BMC Cancer; 2019 Dec; 19(1):1193. PubMed ID: 31805889
[TBL] [Abstract][Full Text] [Related]
40. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]